Dana-Farber & Other Sites Spur New Wave of Clinical Trials of Therapies for T-Cell Lymphoma

Dana-Farber & Other Sites Spur New Wave of Clinical Trials of Therapies for T-Cell Lymphoma

A surge of clinical trials with great potential for promising new treatments for T-cell lymphoma are based on significant basic research momentum made possible by a number of scientists and researchers, reports Dana-Farber Cancer Institute’s Insight blog.

T-Cell Lymphoma

A form of non-Hodgkin lymphoma (NHL), T-cell lymphoma occurs when immune system T cells begin growing and multiplying uncontrollably. With numerous types of the disease in all the entire group of them account for about 10% of NHL cases in America.

Positive Trends

A group of new studies, some opened, some expected to open soon and some completed, represents a major thrust against the disease.

Dana-Farber Research

Back in 2015, Dana Farber’s David Weinstock, MD, led researchers at several institutions in receiving a prestigious SCOR (Specialized Center of Research) grant from the Leukemia and Lymphoma Society to support collaborative research into the disease. The grant was awarded to scientists at not only Dana-Farber but also other institutions and has underwritten research in laboratory cell lines and animal models and set the stage for the new wave of clinical research now underway.

Recent T...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee